DYOR! (Comments?)

Let the trend be your friend! I am assured that this has huge 12 month target and this together with azm, pro should be held for 12 months, or at least if you trade it you should stay involved, apparently all 3 are way undervalued.

I know nothing about the company.I would appreciate if you give me some info/
facts about it - including present price and why you think it is worth me/
anyone buying.Any info is great even if you do not have all of it.Rgds.

Companies web site it: http://www.proteome.co.uk/home.html for research

Thanks...I will have a look

Arjen in shares mag this week there is a full 2-3 page article on all the bios, prm, pro, azm, acambis, oxford bio etc are all featured, good place to start your research for 2.5

good luck

I suppose I better open my Shares mag..............

I am a big fan of this company and have been in since the 30p days topping up on weakness.

Hope this helps on your research it is the Teather and Greenwood note on this company from last month. It explains it pretty well although I think the fair value they put on it is somewhat conservative

Optimum time to invest in key proteomics play
We believe it is now the optimum time to buy into Proteome as its risk
profile has been reduced by the validation of its technologies by key
partners. Furthermore, the vast majority of programmes have yet to be
partnered, providing significant near-term upside to the stock. We
ascribe a net present value to Proteome of 247p per share providing
substantial upside to the current price. We expect further upside to be
achievable as early stage programmes move towards partnering and
commercialisation.

__ Investment profile -Proteome is a leading pure play proteomics company
performing drug target and biomarker development. Rather than looking to take a
portfolio approach in gaining exposure to the field of proteomics, due to lack of companies in this field we suggest buying into Proteome alone. Its range of
technologies and programmes provides an investment that gives exposure to
proteomics biomarkers, drug development and proteomics reagents and
technologies. The range of technologies and programmes possessed by Proteome
also reduces exposure to the risk of product failure through a decreased reliance on individual products.

__ Validated technology and strong news flow -Proteomes technology has
already been validated by the industry with the announcement of the licensing of
biomarkers to two leading diagnostics players over the last 12 months. We expect
diagnostic tests using these biomarkers to be launched by the partners in 2004. A wealth of further licensing agreements are likely to be signed for the
commercialisation of other biomarkers against additional diseases that have either been identified or will be identified in the future. Further deals are also likely to result from research alliances with pharmaceutical and biotechnology companies looking to develop therapeutics against novel targets that Proteome is capable of identifying and characterising.

__ Near-term profitability -We forecast that Proteome is currently on the cusp of moving into profit, which combined with the current cash position, will allow
Proteome to be self-funding going forward. This should result in there being little prospect of future dilution for current investors, unlike many other investments in this sector which will need further fundraisings.

__ Significant upside -Our current NPV model for Proteome suggests a fair value
of 247p per share for the stock. This is a significant premium to the current price and provides the prospect of substantial upside to investors as future
developments drive the price of the stock towards our perceived fair value. The
companys late stage pipeline accounts for the vast majority of the value. We
believe there is a low risk of failure to reach market for the late stage programmes and therefore believe there is little developmental risk to our valuation. In addition, as earlier stage products advance, the increase in size of the portfolio will further spread the risk of individual developmental product failure

If you seriously want to know anything about PRM, I strongly suggest you read the PRM BB on ADVFN. Some useful links in the header and a history of very informative posts from a plethora of very well respected posters. I particularly recommend reading posts from jt, Tuco, Steverob, Maxwellsdemon, Goatherd, Fandango, Square1 and others to whom I apologise for not remembering off the top of my head.

Thanks to all for taking the time to give such good info.
It seems - on first impressions - to have a lot of potential.aj

I put the two day chart on this thread, because I'm an investor who likes to trade. And this is a share which is currently giving that opportunity!

Amazingly good news today I topped up on the news

RNS Number:9656R
Proteome Sciences PLC
12 November 2003



PROTEOME SCIENCES plc

PRESS RELEASE


Proteome Sciences Awarded Grant of US Patent For Diagnosis of Three Major
Cancers

Proteome Sciences plc ("Proteome Sciences"), is pleased to announce that it has
today been granted US Patent No. 6,645,465 entitled "Annexin Proteins and
Autoantibodies as Serum Markers for Cancer".

Annexins are a class of at least 12 different proteins with a putative role in
controlling cell signalling and metabolism. Elevation of certain annexins
correlates with various diseases. Work funded by Proteome Sciences led to the
discovery that anexins I and II are elevated in three major cancers, namely
lung, breast and oesophageal cancers. Significantly, it was possible to develop
a test that could detect antibodies to these proteins in the blood of patients
with tumours, but not in healthy individuals.

The granted patent includes claims to the use of annexins and antibodies to them
in the diagnosis of lung, breast and oesophageal cancers, which collectively
account for an estimated 400,000 new cases each year in the US, roughly 1
million worldwide. Proteome Sciences is actively pursuing partners to co-develop
new diagnostic and prognostic tests based on detection of annexin
autoantibodies, in line with its long-standing practice of partnering
activities.

Commenting on the announcement, Christopher Pearce, Chief Executive of Proteome
Sciences said :

"We are very pleased to see the grant of a key patent for an important class of
cancer biomarkers. This is the first of a series of patents to be granted from
our research in cancer and which underpins the value of our early programmes in
biomarker discovery. This allows us to secure strong commercial partnerships to
develop new diagnostic and prognostic assays for these important diseases where
diagnosis is often made too late for effective treatment and to accelerate the
development of therapeutic targets.


Using its ProteoSHOPTM tool box Proteome Sciences is focused to discover and
validate new biomarkers across a broad range of major diseases including
neurodegeneration, neuroscience, diabetes/obesity, cardiovascular disease and
cancer, which, together with its strong portfolio of existing intellectual
property, places us at the forefront of applied proteomics.".


- Ends -

Notice GNI topped up to the tune 1.3M shares on Friday/last week, that's confidence.

A :- Result of E.G.M.

B :- Dr G.W.Schmidt resigned ------------- Frankfurt facilities.

Agreement with Medical Research Council

Appears - to me - to be Very Positive to the extent I think everyone on the
tread should read it rgds aj

Directors Interest:-

Dr Sandra S.Steiner

Looks like this has started moving up again.

I am amazed there is such a lack of interest/few posts on this share as it is
a very interesting one.aj

Today + 1.00 / + 0 .51 per cent

No, I'm very interested and have posted such on numerous occassions!

Meant to post this while back. Its a good profile on PRM.

http://www.pharmaco-genomics.co.uk/admin/files/PGS040515.pdf

Has PRM peaked? Or has it further to go?

IMHO this has a lot further to run, credit lyonais upped it's stake this week and the directors have bought big style, also changed advisor, I think this is still early days and I'm adding more.

Dam dam dam, missed it, should of bought last night, thought it woul push down one last time, still I think will move to new highs 3 target or q1.

Mmmmhhhh - wondered whether to post as most investors hate to hear about negatives. So just a couple of thoughts in summary and dyor.

1. Check out the fundamentals - valuation vs sales vs future potential royalty income stream.

2. Primarily a diagnostics test development Company - check out the biggest diagnostic players/their turnovers/profits etc. To give you a start - look at Roche/Abbot and Axis Shield platforms/products and how they are sold. Whose platforms will PRM's tests go on to and what is average take? Plus latest in-vitro, simple urine/blood tests cost less than 3c per strip to produce. Work out the quantity of tests/likely royalty income stream should the strips replace some of the more complex assay test platforms used in labs. Did you know there are already simple blood test strips for detecting cancer? Further tests are then done to determine the specific type/location.

3. Why are PRM's diagnostic markers better than existing/others also being developed? At the end of the day the cost of the test/accuracy will determine sales/income levels. Also approval FDA/EU for in-vitro diagnostic systems are simple/fast compared to treatments/drug testing so lead time/patent benefits very limited. Generic/copying with marginally different assays/procedures a problem in diagnostic testing.

4. PRM has been hyped tremendously and often last pump before the decline (end of the push) is takeover rumours which have now surfaced.

In summary this Company is valued at some 250m - work out the number of tests that need to be sold and future royalty income stream to back up this valuation.

Having said all the above I should point out I bought in at under 40p and sold far too early so wtfdik and this could still go to 250 or higher. No position currently.

Good luck everyone.

Suggest today's rise is as a result of Shares making it one of their tips for 2004 (p22).

Rise was because of bse news in the States. Look at PTI first though, it's on the market testing dead carcasses!! PRM do a live test eventually, trouble with that though is the fact the animal can be infected an hour later?!

Hi, my 1st contribution here.

Made good profit on PRM !!! but sold far too soon ! about 140.

I like this format... its like ADVFN which I know.

ADVFN seems dead this weekend so I've joined here...

I'll be trying things...

Buy Proteome Sciences at 200p Argues Andrew Griffiths of The AIM &OFEX Newsletter [links to https://secure.redskyresearch.com/images/aim_ukanalyst_trial.html]

Proteome Sciences is a biotech fledgling that is becoming something of a darling among City life sciences analysts with the shares trebling last year. A hefty research tome from Evolution Beeson Gregory just before Christmas added to the intellectual firepower supporting the price.
To the uninitiated, Proteome might appear to be just another biotech hopeful with no profits and an inflated market capitalisation. Those with long memories will remember the company as Electrophoretics, one of the earliest AIM entrants, and one that always seemed to be promising a breakthrough tomorrow. But nearly a decade after its public company debut and with the same management in place, a positive consensus finally appears to be emerging among analysts about its potential.

Many believe this "technology rich" life sciences company can translate its commercial potential into big revenues, starting from next year, and the market looks like believing the story. Proteome is a significant player in the field of proteomics - the "next revolution in drug discovery" according to some - the analysis of proteins within a cell. The discipline identifies relevant genes and proteins as potential targets for drugs and for diagnostic tools, so producing a new way of identifying and targeting disease.

The technology has allowed the company to identify "biomarkers" within cells, which can be used to diagnose diseases. Proteome has licensing agreements for a stroke biomarker, which can identify whether a patient has suffered a stroke, and a TSE (transmissible spongiform encephalopathies) marker, which may be used to diagnose BSE ("mad cow disease") within cattle and CJD in humans. Each could generate significant royalty payments and the company has another ten markers in the offing. Evolution estimates that the world proteomics market is worth $1.5bn (800m) and is expected to grow at around 20% each year for the next five years.

As far as revenues go, the broker is forecasting sales of 700,000 for the current year, rising sharply to 2.9m in 2004. But it does not expect the company to break even until 2005. Fortunately, Proteome Sciences has the cash (more than 6m) to see it through until then.
Beyond 2005, Evolution expects annual revenues to snowball into tens of millions of pounds. The forecasts rather optimistically assume that each commercialised marker will be used to create a diagnostic product and a pharmaceutical, and that the company will license an average of 1.5 markers per year.
Whether all this is enough to justify a 228m market capitalisation is a moot point but Proteome appears to be making its best progress for a decade. Brokers believe the shares have further to go, which makes them an interesting speculation. Buy. Key Data


EPIC: PRM
Market: AIM
NMS: 10,000
Spread: 199p-201p
Market Cap: 228 million

Andrew Griffiths is managing editor of The AIM &OFEX Newsletter, which specialises in digging out fast growing shares from London's junior stockmarkets. Recent successful tips include Datacash up 252%, Fayrewood up 142%, and Epic Group, up 125%. For a two issue free trial click here [links to https://secure.redskyresearch.com/images/aim_ukanalyst_trial.html].

More good news
GRANT OF US CANCER PATENT FOR NEUROBLASTOMA AND GLIOMA IN BLOOD


http://www.uk-wire.com/cgi-bin/articles/200401260841586140U.html

Why has no one posted any messages for over a month? Have you all sold up and moved on?? New to the site and have found the messages interesting reading. Can not make my mind up whether to sell proteome now or hold on. I read one article recently that told readers to get out of proteome fast but other forecasters seem positive. Its gone down to 206p today. Be intersted to know what anyone elses thoughts are.

after the all the recent falls to low of 139p today ...level 2 is now showing upward movement by the mm's ... recent rns by co no reason for price fall .. now around 143p

Bouncing back nicely - hopefully back to the 2 level.

Barrowboy! Sorry Boroboys

How much of this stock are you now holding


Just been looking at the graph..????

Things are not looking good, I can not help but feel pessamistic when it comes to Proteome Sciences after investing a substantial figure in the company, nothing in real terms but a hell of a lot for a 19 yr old student I am fearing the worst. Whats everyone else thinking?

gild18er
Have you got a stop-loss in place?
I fear that on no news these will fall even further. I am watching from the side-lines to buy in but don't want to catch a falling knife. On balance I believe in their 'story' but further drastic falls may force their hand to make an announcement more substantive than their last one. And when will that be? Tomorrow, or days, weeks, months? Thats the uncertainty of it all.
If you are over 30% down then IMHO I'd hold and ride it out. If less perhaps sell and try and get back in at a lower price. Or a mixture of both. But then this is just my view. I'm sure others would disagree. In the end its your call. Good luck.

Gild18er, you should sell and cut your loss. Don't hold out for a bounce in the price, it may fall a lot further before it comes.

What about getting in now? Big drop and now at 122 to buy? Have not held before but just sold BGY to lock in profit - I know they're still going up but I'm chicken. Or anything better today to go for???????

amberjane
Tricky to call the floor on these at the moment, but I think if you look at the medium to long term ( but don't discount the short term)you would be getting in at a good price, and if you have faith in their story, which I do then you can ride out the current volitility. I wouldn't be suprised if they dropped more after a little rally over the next couple of days or so but wouldn't count on it. If there is very heavy buying tomorrow it could suggest the floor has been reached. My conclusion is to stay out at the moment, why take such a risk?
For another to go for try BPRG. A large contract plus broker's note is imminent and the price is relatively low at the moment. In fact if you get in tomorrow (wednesday) before it you will be lucky. We have been told by management within two weeks but rumours are flying that the brokers note is due Thursday, so the contract should (but anything can happen)be announced before or with it. I am very heavily into these. No ramp intended. DYOR.

No e-mail to contact u direct but thanks, what price is good for BPRG today, don't have level 2, abowt 113?

OT
amberjane
113 is good at this stage IMHO. 110 has proved a good support in the recent past so its not too far off. Some on another BB think maybe early next week if not this week for Brokers note and contract so don't panic if its not out by Friday. All rumours etc to be treated with a healthy pinch of salt! Its close though. Are you aware of the another BB starting ADV..? Good threads there on BPRG and research website given in the header of the main one. If you can't access the BB the research web page is: http://mysite.freeserve.com/bprg/index.html
Good luck

Many thanks, will consider. Ta

Well did my research and decided, went to buy and after my first quote at 114 upped the amount & it went to 116 :-{{{{

Oh sorry, excellent for all you holders. Luv me x

Hope you have called the bottom right Amberjane but fear its got further to fall. Guess we will know tomorrow. I got out yesterday.

I consider 105 to be a good bounce off point...still a bit worried as it might fall further as Antisoma did a couple of days ago but I reckon 105p will offer good support..

Yes agree mitzy, now I've had excellent training on how to read charts and work out what they mean! 105 would be good price to buy in at. Perhaps I should have put this on the right thread, sorry if I'm confusing anyone, had a strange e-mail. x

Crikey, still free-falling this morning. I pity the poor blighters still holding. One thing though, there is going to be one massive bounce back up when it comes. Are you ready?

Biotech stocks being further derated, risk premuim being reduced.

It has gone right through 105p - its support point - and i think it will be falling right to 65-75p in the next few days. STRONG SELL!

Somebody keeps buying...There were rumours of a take over some time ago at 5. Who would not accept 1.50 now ?

I think (hope) the bottom has been reached and bought back this afternoon

Proteome at its highest worth only 2.40 in 1998. Nobody would offer 5 for it. It is a SELL.

From HODBOD on ADVFN -
I have not posted on this thread before. I have held shares in PRM since early 2001 having become aware of the Company through the bulletin board.In spite of the confidence shown by some fellow investors and the detailed reasoning that leads the bulls to the development of financial forecasts that justify huge future valuations for the Company,I have not changed the view I formed when I bought the shares. PRM are a highly speculative investment that may in time yield high returns because the Company is in at the early stages of a new technology that promises the prospect of exponential growth for those Companies that are sucessful. However, there is a higher probability that PRM will fail to develop as a major company and may even fold up because that is the nature of the process by which high tech tadpoles turn into mature financially successful frogs.

New technology is exciting but it is extremely difficult to make forecasts about the commercial prospects for any particular piece of IP especially when it is in the hands of a small developing company.

Adopting the analogy of the computer industry, in 1990 there were zillions of companies that were developing both hardware and software that was mind boggling in terms of its superiority over the technology that existed in 1980.However, relatively few of them developed into major companies because the challenge of commercialising their technology was beyond the capabilities of the company, or the technology was not competitive compared to developments that were taking place simultaneously in other companies and that would not become public knowledge until the competition judged the time was right to launch it.

PRM have some exciting IP. What that means in terms of the future fortunes of the company and the share price depends to a great extent on what is happening elsewhere as well as on how well managed PRM itself is. It is also imperative that the small investor does not lose sight of the fact that this is a small company and that neither the financial markets or the large players in the biotech industry are going to be anything other than ruthless in trying to take advantage of a small vulnerable company if the opportunity arises.

Don't blame the management because they can't fulfill your dreams on the day you require them to be fulfilled. Have the maturity to recognise that we are all seduced by the prospect of having a dream come true,especially if it could have happened by April 9th. Take this opportunity to reassess the realities of the situation and decide whether this is a share in which you should be investing Personally, I still feel that there is enough substance in the company to justify risking my entire stake, but I acknowledge a significant probability that they could return to the price atwhich I purchased them or they might even become worthless.

To the people who have genuinely given me the benefit of their knowledge and insights I offer my thanks whether they seek to argue that the company is bound for huge success or put forward carefully crafted explanations as to why they feel that such optimism is misguided. You have all provided me with a base from which I could make my own judgements and exercise my own instincts.Please continue to provide me with informed opinions. I accept them as opinions and nothing more or nothing less.

As for the people who seek to undermine confidence in the company and warn that doom is around every corner, I must recognise that they are playing a different game and accept them as a fact of life. It is as pointless to complain about them as it is to complain about the existence of gravity.
However, I would add that posters like NNN who merely scream banalities and do not feel that the rest of us are worthy of the courtesy of a reasoned argument do try my patience. If my prayers are answered their extremities will rot.

I feel that the next 12 months is a critical period for my investment in PRM. To date I have been interested and patient, but 12 months ago there was a significant change in the declared prospects for the Company when the Management gave strong indications that commercialisation of IP was on the horizon, if not immminent. Given the nature and complexity of IP licencing I can understand that precise timing is difficult. However, unless there is confirmation of actual revenue generating deals before the end of 2004 it will be hard to avoid the conclusion that there probably is no end to this particular rainbow.

Market Report: Bear raiders make profits on Proteome Science
By Michael Jivkov
30 April 2004


Bear raiders moved in on the biotech group Proteome Science yesterday and, given the stock's dramatic 19 per cent slide, they look to have made a packet. The raiders are believed to have noticed some time ago that there were a large number of private investors holding the stock via contracts for difference.

These allow investors to gain exposure to, say, 100,000 worth of shares in Proteome, but only put up a fraction of the money in hard cash. This means that private punters can turn a relatively small amount of money into a lot more. But it also means that when a position goes the wrong way for an investor he can quickly find himself nursing a large loss and being urged by the broker offering him the contract for difference to close his position and sell out.

This is what many private punters were forced to do yesterday as bear raiders pushed Proteome shares lower. And the further they fell, the more punters were forced to close their positions, which in turn pushed the group's shares even lower. They ended the day 21p lower at 88.5p.

Proteome's stock has halved over the past month but market professionals believe it is unlikely to fall any further, noting that nothing has fundamentally changed at the group during this period. Among them was Evolution Beeson Gregory. The broker reiterated its "buy" rating on Proteome and tipped newsflow from the company in the near future to help rally its shareshttp://news.independent.co.uk/business/analysis_and_features/story.jsp?story=516595

UK smallcap opening - Proteome Sciences rally after reports of CFD pressure
Fri 30 Apr 2004 08:33

LONDON (AFX) - Shares in Proteome Sciences rallied by 6 pct in opening
trade, having fallen 19 pct yesterday amid reports the stock was being squeezed
by trading related to a large spread-betting contract known as a contract for
difference (CFD).
According to the Daily Mail, market-maker Winterflood took out a CFD
contract with IG Index then marked the stock down to attract buyers. However,
buyers failed to materialise, the newspaper reported.
Other newspapers suggested that yesterday's fall had triggered margin calls
on holders of CFDs on the drug developer, who have been caught in a downward
spiral.
At 8.14 am, shares in Proteome were ahead 5 pence to 93-1/2.

Janus,

Thank you for your sensible posts. Made me think about several tiny shares I've been chasing recently and losing sleep over.

I aggree wholeheartely about NNN & co.

EVBG report 1st June

Proteome Sciences (PRM) Buy (unchanged)
Mkt cap: 139m Net cash: 4m Update Price: 116p
Slowly, slowly catchee monkey
Proteome is making good progress towards commercialization with both biomarkers and technology, although deals have been slower than anticipated. Mid-term this is an investment with significant potential.

An update meeting with Proteome Sciences last week confirmed our view that the business continues to make progress towards commercialization.

Although new deals have not materialized as fast as we would have liked we are confident that progress is being made with both the commercialization of biomarkers and the underlying technology. The broader trend within the pharmaceutical industry towards personalised medicine (for example the recent data on IRESSA) indicates increasing interest in biomarkers for both identification of patient groups and the targeting of new drugs. Proteome has significant expertise and good IP in this area.

The table on page 4 gives a broad indication of when announcements on commercial progress are now expected. As many of these deals take some time to negotiate we have broadly grouped time to newsflow into near-term (less than 12 months) mid-term (12-18 months) and long term (greater than 18 months). As can be seen from the table there is significant activity in many areas.

The two existing biomarker collaborations are also progressing well. The relationship with Biosite to develop a point of care test for stroke involves close collaboration between the parties. Biosite is expecting to launch a point of care test for stroke in the next 12 months. The panel has not yet been finalized; it may include public markers, and/or proprietary markers from Proteome or Biosite. Clinical trials of the final panel are due to begin shortly with submission to the FDA due by the year end.

The IDEXX collaboration on a pre-mortem BSE test is also progressing to plan, although the company has not released any additional information. Internally Proteome has turned its attentions to a human new variant CJD test with an eye on the blood screening market. The company has reached agreements to give it access to samples from CJD patients, this is key to the identification of markers and subsequently a test.

In the technology area we are expecting newsflow relating to both ProteoSHOP and some of the mass spectrometry reagents (including the Sensitizer family). The latter are proving more complex than initially anticipated with many options available to Proteome. In the ProteoSHOP area Proteome remains committed to long term value added relationships which extend beyond fee for service. These types of deals take longer to negotiate. Since the market for pharma outsourcing has been weak over the last 12 months (see our comments on BioFocus) it is perhaps not surprising that a deal has not been signed as yet. The outsourcing market is now improving with more discussions underway, and although pharma companies remain reluctant to commit to large collaborations we would expect smaller, exploratory, proof of technology type deals to be achievable. Once the technology is proven we expect these to translate into bigger contracts.

Proteome announced new data at the American Society for Mass Spectrometry Meeting last week. The company has used its ProteoSHOP technology to identify novel phosphorylation sites and the kinases responsible for Alzheimers. This takes Proteome Sciences for the first time into high value identification and discovery of new drug targets using proteomics. The technology should now be used in the identification of potential drug targets in other disease areas. This paper shows the value of ProteoSHOP in drug discovery and we believe it will generate further interest and commercialisation opportunities from this technology.

Proteome continues to have a low cash burn rate. It reduces cash outflows further through grants and we expect initial milestones from both Biosite and Idexx to be achieved this year. This leaves the company in a solid cash position. The delivery of news flow will be key to driving the price beyond
the current level. The company will be active in this area over the next 12 months consequently we reiterate our buy recommendation. Final results from YE Dec 2003 are expected to be announced on 28 June.

Year end Sales (m) EBITDA (m) PTP (m) EPS (p) PER (x) Net Cash (m) Cash Burn (m) Revised?
12/02A 0.2 -3.5 -4.1 -4.0 - 4.3 3.4
12/03E 0.7 -4.3 -4.9 -4.0 - 6.3 3.7 No
12/04E 2.9 -2.0 -2.5 -1.7 - 3.4 2.5 No

Biomarker commercialisation

Therapeutic area Application Validation Licensed Product launch

Stroke POC Complete Complete (Biosite) Near term
High throughput Complete Near term
TSEs* Animals Complete Complete (Idexx) Mid term
Man Ongoing Mid term
Alzheimers Biomarkers Ongoing Mid term
Target Ongoing Mid term
Cancer Lung Complete Mid term
Lung vaccine Mid term Long term
Breast Complete Mid term
Oesphagus Complete Mid term
Neuroblastoma Complete Mid term
Organ Rejection Acute coronary Complete Mid term
Chronic coronary Complete Mid term
Renal Ongoing Long term
Metabolic Type II diabetes Ongoing Long term

Technology Commercialisation

Application Validation 1st Deal Follow-on deals

ProteoSHOP Biomarkers Complete Near term Mid term
Targets Complete Near term Mid term
Toxicology Complete Near term Mid term
Reagents Sensitizer Family Complete Near term
Antibodies Ongoing Mid term
guide to future performance.

Placing to buy more Intronn

http://www.uk-wire.com/cgi-bin/articles/200406040700144112z.html

Well Fidelity certainly have confidence in this

RNS Number:6207Z
Proteome Sciences PLC
10 June 2004


Proteome Sciences plc ("the Company")

Proteome Sciences plc was today advised that FMR Corp. and its direct & indirect
subsidiaries and Fidelity International Limited and its direct and indirect
subsidiaries and Mr Edward C. Johnson 3rd (A principal shareholder of FMR Corp /
Fidelity International Limited) have a notifiable interest in 9.861,382 ordinary
shares, representing 8.06% of the companies issued ordinary share capital.


This information is provided by RNS

The company news service from the London Stock Exchange

END
HOLGUUCWQUPCGUU

Anybody apart from me still in these. Lovely rise over the last few days something in the wind ?

I was thinking about this 1 last month but then I forgot about it.

Just look what happened while my back was turned. Up 46%

I'm long on PRM and purely on the Chart, didn't even know what they did, (which might be a bit of a mistake), but the chart was screaming out BUY, so I took the plunge. Very dependant now on the results and if they have managed to secure deals to produce revenue. Without a deal they will probably need to find more cash next year and the SP will tumble once more. Will probably know more soon.

Regards

PTH